Pre-market Hot Trades in US Stocks
Abits, up 30.81% in pre-market, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
HPE is up 29.77% in pre-market. Based on recent key news:
<ol>
<li>
On June 1, Hewlett Packard Enterprise released its second-quarter financial report, with revenue increasing by 40% year-on-year to $10.68 billion, exceeding market expectations. Earnings per share were $0.79, far exceeding the expected $0.53, driving the stock price up 28.04% in after-hours trading. Source: Zhitong Finance
</li>
<li>
On June 2, the company raised its revenue growth forecast for fiscal year 2026 to 29% to 33% and increased its adjusted earnings per share guidance to $3.35 to $3.45, significantly higher than previous expectations. This optimistic financial outlook further stimulated the stock price increase. Source: Wall Street Insight
</li>
<li>
On June 2, HPE launched a new generation of ProLiant servers equipped with NVIDIA Vera CPUs, designed for Agentic AI, as market demand for its AI infrastructure increases, pushing the stock price to a historic high. Source: Jinshi Data AI and cloud computing demand is strong, driving industry growth.
</li>
</ol>
Top Gainers in Pre-market US Stocks
Decent, up 141.68% in pre-market, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
VisionSys AI, up 90.25% in pre-market, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Sunshine Biopharma is up 59.22% in pre-market. Based on recent key news:
<ol>
<li>
On June 1, Sunshine Biopharma received approval from Canada to produce the generic drug rivaroxaban tablets. This drug is a generic version of Bayer's Xarelto anticoagulant, planned to be launched in October 2026 through its Canadian subsidiary Nora Pharma's distribution network. This news significantly boosted the company's stock price.
</li>
<li>
On May 29, Sunshine Biopharma released relevant content through the EDGAR system of the U.S. Securities and Exchange Commission, highlighting the company's expectations in drug development activities, financial performance, and future growth. These forward-looking statements may affect investor confidence, further driving the stock price up. The competition in the pharmaceutical industry's generic drug market is fierce
</li>
</ol>

ABTS

Abits pre-market up 30.81%; Hewlett Packard Enterprise pre-market up 29.77%; Decent pre-market up 141.68%; VisionSys AI pre-market up 90.25%; Sunshine Biopharma pre-market up 59.22%

Price Alert

Abits

Pre-market hot trades in US stocks: Abits up 30.81% pre-market; Hewlett Packard Enterprise up 29.77% pre-market